Health Care · Pharmaceutical Preparations

XENE Xenon Pharmaceuticals Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1582313103 filings
Russell 2000

XENE at a glance

Xenon Pharmaceuticals Inc. (XENE, SEC CIK 1582313) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Xenon Pharmaceuticals Inc. (XENE) reported revenue of $7.5 million and a net loss of $345.9 million. Diluted EPS was -$4.36.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Xenon Pharmaceuticals Inc. (XENE) shares worth $844.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by MORTIMER IAN on September 30, 2026 of 30,000 shares at $37.38 per share.
  • In the last 90 days, XENE insiders reported 2 open-market purchases ($1.7M) and 2 open-market sales ($426K) on Form 4, a net purchase of $1.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$7.5M
10-K XBRL
Insiders · 90 days
2 buys · 2 sells
Net +$1.3M
13F holders
27 funds
$844.3M · −5 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: neuroscience-focused biopharma discovering and commercializing novel ion channel modulators for neurological and psychiatric disorders
  • New emphasis on azetukalner in Phase 3 for epilepsy (FOS and PGTCS) and depression (MDD and BPD), with multiple late-stage studies ongoing
  • Strategic shift: advancing first Kv7 potassium channel opener with potential rapid onset and once-daily dosing, targeting difficult-to-treat epilepsy and neuropsychiatric indications
  • Notable metric: 380 patients enrolled in pivotal Phase 3 FOS study (X-TOLE2), seizure reduction up to 52.8% at 25 mg dose, ongoing 7-year open label extension with 46% retention at 48 months
  • Early-stage pipeline expansion into pain with initiation of Phase 1 studies for two novel candidates targeting Nav1.7 and Kv7 channels, exploiting genetic validation for new pain treatments

Risk Factors

  • Regulatory risk: alignment with Japan’s PMDA to enroll ~60 of 360 X-TOLE3 participants in Japan, affecting regulatory submission timing
  • Macroeconomic risk: foreign exchange exposure to Canadian dollar fluctuations impacting monetary assets and liabilities
  • Operational risk: reliance on successful completion of late-stage Phase 3 clinical trials for azetukalner, including X-TOLE2 topline data expected March 2026
  • Competitive risk: collaboration with Neurocrine Biosciences on NBI-921355, targeting epilepsy, poses potential competitive or partnership dependency risks
  • Financial risk: accumulated deficit $1.245 billion, net losses increasing to $345.9 million in 2025, requiring ongoing equity/debt financing with no product sales revenue yet

Management Discussion & Analysis

  • Cash flow, buybacks, dividends, or capital expenditure figures not included
  • Forward-looking statements involve risks and uncertainties, no specific guidance or outlook provided

AI summary of the XENE 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales
  • Quarterly loss before taxes $108.6M vs $90.2M YoY, R&D expenses $95.6M vs $77.1M
  • Azetukalner worst cost driver: R&D $54.5M, up $11.8M YoY
  • Cash and securities $1,153.5M at September 30, 2026, supported by $843.3M financing inflows
  • Operating cash outflow $274.6M for nine months, up from $197.6M YoY; funding expected for at least 12 months

Risk Factors

  • Newly triggered regulatory risk: azetukalner NDA submission to FDA in September 2026
  • Clinical-development risk: voluntary pause on new enrollment in Phase 3 MDD and BPD studies announced in September
  • Financial risk: $323.5 million nine-month net loss and $1,568.9 million accumulated deficit
  • Liquidity risk: $1,153.5 million cash and marketable securities expected to fund operations for at least 12 months
  • Currency risk: unhedged Canadian-dollar exposure, including CAD$57.5 million in cash and marketable securities

AI summary of the XENE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Press release Exhibit 99.1 contains the reported financial figures and management commentary

Item 7.01: Regulation FD Disclosure

  • Xenon designates its website, investor-relations site, news releases, X account, and LinkedIn as channels for potentially material disclosures
  • Investors should monitor these channels alongside SEC filings for updates on product candidates and corporate developments

Item EX-99.1: Item EX-99.1

  • FDA NDA for azetukalner in focal seizures submitted September 2026, advancing Xenon toward potential commercialization
  • X-NOVA2 MDD enrollment completed at approximately 360 patients, with topline results expected December 2026
Filed Aug 6, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor communications may contain material information across SEC filings, press releases, calls, company websites, and social media
  • Key monitoring channels include @XenonPharma on X, LinkedIn, and investor news releases

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss $110.7M versus $84.7M, reflecting accelerated investment in azetukalner and pain programs
  • Cash, equivalents and marketable securities $1.245B, supporting operations into 2029 and reducing near-term financing risk

Item 2.02: Results of Operations and Financial Condition

  • Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
  • Detailed results and management commentary provided in Exhibit 99.1 press release
Filed Jun 3, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 93.54% shareholder participation, with 90,399,636.29 shares voted or represented by proxy
  • All eight director nominees elected through 2027, with opposition ranging from 388,586.65 to 4,517,221.65 votes

AI summaries of XENE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for XENE

Don't miss the next XENE filing

  • Alerts as it files. A push when XENE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut XENE, by share count.
  • Ask anything. An AI agent that reads every XENE filing and answers with sources.

XENE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kelly Thomas PatrickMOct 15, 2026-
Kelly Thomas PatrickMOct 15, 2026-
MORTIMER IANBuySep 30, 2026$37.38
Kelly Thomas PatrickBuySep 30, 2026$37.32
Svoronos DawnMSep 1, 2026-
Svoronos DawnMSep 1, 2026$8.15
KENNEY CHRISTOPHER JOHNSellAug 28, 2026$60.17
KENNEY CHRISTOPHER JOHNSellAug 28, 2026$60.98

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$7.5M
Operating Income--$279.3M-$373.1M
Net Income-$182.4M-$234.3M-$345.9M
Op. Margin---4974.3%
Net Margin---4612.1%
Balance Sheet
Total Assets-$798.1M$633.2M
Equity$927.9M$754.9M$581.8M
ROE-19.7%-31.0%-59.5%
Per Share
EPS$-2.73$-3.01$-4.36
Cash Flow
Operating CF--$181.4M-$279.1M
CapEx$5.6M$3.1M$799K

Source: XBRL data in Xenon Pharmaceuticals Inc. (XENE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate XENE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
XENE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$844.3M
Q2 202632$2.14B
Q1 202629$1.74B
Q4 202526$1.08B
Q3 202527$1.01B
Q2 202525$711.7M
Q1 202523$469.6M
Q4 202419$415.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 208 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

XENE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Oct 16, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Sep 3, 2026--
4Aug 31, 2026--
4Aug 13, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 3, 2026Analysis
4May 13, 2026-
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
8-KApr 13, 2026Analysis-
4Mar 13, 2026--
4Mar 13, 2026--
8-KMar 13, 2026Analysis-
4Mar 13, 2026--
8-KMar 12, 2026Analysis-
4Mar 11, 2026--
4Mar 11, 2026--
4Mar 11, 2026--

Related Health Care companies

All Health Care →

XENE SEC filings: frequently asked questions

Are XENE insiders buying or selling?

In the last 90 days, Xenon Pharmaceuticals Inc. (XENE) officers, directors and 10% owners reported 2 open-market purchases worth $1.7 million by 2 insiders and 2 open-market sales worth $425,829 by 1 insider on Form 4, a net purchase of $1.3 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold XENE stock?

As of September 30, 2026, the largest Xenon Pharmaceuticals Inc. (XENE) holders among the 13F filers tracked by SignalX were BlackRock ($286.8 million), T. Rowe Price Group ($118.2 million), State Street Corp ($76.5 million), Franklin Resources ($56.6 million), Two Sigma Investments ($53.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was XENE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Xenon Pharmaceuticals Inc. (XENE) reported revenue of $7.5 million and a net loss of $345.9 million. Diluted EPS was -$4.36. The figures come from the XBRL data in the 10-K.

What are the main risks in XENE's latest 10-K?

In the 10-K filed February 26, 2026, Xenon Pharmaceuticals Inc. (XENE) flagged: Regulatory risk: alignment with Japan’s PMDA to enroll ~60 of 360 X-TOLE3 participants in Japan, affecting regulatory submission timing. Macroeconomic risk: foreign exchange exposure to Canadian dollar fluctuations impacting monetary assets and liabilities. (AI summary of the Risk Factors section.)

What did XENE report in its latest 8-K?

Xenon Pharmaceuticals Inc. (XENE) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.

What are the latest XENE SEC filings?

Xenon Pharmaceuticals Inc. (XENE) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 16, 2026.

What is XENE's SEC CIK number?

Xenon Pharmaceuticals Inc. (XENE)'s SEC Central Index Key (CIK) is 1582313. EDGAR lists every XENE filing under that number.

Ask anything about XENE

The research agent reads XENE's filings, financials, insider trades and 13F holders, then answers with sources.